EyePoint Inc. announced mixed Phase 3 clinical trial results for its wet AMD drug, DURAVYU, causing its stock to plummet. While secondary endpoints showed significant progress, the primary visual acuity endpoint was missed due to a confounding patient subgroup, raising concerns about the drug's market viability.
EyePoint Inc. (EYPT) released topline data from its pivotal Phase 3 LUGANO trial for DURAVYU, a wet AMD treatment. The trial failed to meet its primary visual acuity endpoint, leading to a significant stock plunge of over 70%. This is a major setback for the company's lead product, as the primary endpoint is crucial for regulatory approval and market adoption. Although secondary endpoints were positive and an ad hoc analysis showed non-inferiority when excluding a confounding patient subgroup, the initial miss creates uncertainty and will likely delay or complicate the New Drug Application process. Traders face significant short-term downside risk due to the uncertainty surrounding DURAVYU's path to market, despite the long-term potential if subsequent trials (LUCIA, COMO, CAPRI) yield clearer positive results.